Our understanding of the paramount importance that epigenetic regulation exerts over disease progression has grown in the past decade. Not only do epigenetic mechanisms govern the course
of disease, but they also inform the likelihood of ever developing disease. Importantly, epigenetic mechanisms are plastic and can be modified with in life interventions ranging from diet and
exercise to use of drugs. I will highlight how epigenetic inheritance affect course of liver fibrosis development and describe the mechanisms behind these predispositions.
This workshop will discuss:
Jelena Mann, Professor of Epigenetics, Fibrosis Research Group , Newcastle University
I am interested in delineating epigenetic signalling pathways that trigger fibrogenesis and in doing so, discovering molecular control of fibrogenesis and associated signalling pathways that can be targeted with new as well as existing drugs. More recently we have also embarked on studies that test the ability of environmental factors to affect transgenerational inheritance of predisposition to liver fibrosis. Adaptation to environmental insults is critical for ensuring fitness and survival of the species, however it is currently not clear if predisposition to development of fibrosis exists or indeed if existence of disease in previous generations alters such predisposition.
Stratified Medicine Scotland – Innovation Centre (SMS-IC) is focused on linking Scotland’s domain expertise, data assets and delivery capability to accelerate the adoption of precision medicine for more effective medicine development, better diagnostics and earlier intervention, and optimal treatment selection.
Join your peers to review latest research on:
Speaker TBC, ,
Systems biology is an interdisciplinary field that studies the complex interactions within the liver, other tissues and gut microbiota using a holistic approach. Detailed insights into the
biological functions of the liver and its crosstalk with the gut microbiota can be used to develop novel strategies for the prevention and treatment of NASH, and facilitate more efficient drug development decisions.
This in-depth session will focus on:
Adil Mardinoglu, Professor of Systems Biology , Kings College London
In the last year, the NASH drug development landscape has seen the emergence of novel drug candidates and varying success in the advancement of existing candidates. Now with the very
earliest NASH drug looking to hit the market in 2021, questions surrounding clinical development strategy and regulatory intelligence before and after an accepted drug are pivotal to the field.
This workshop will cover:
Richard Torstenson, Independent Regulatory, Advisor